We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Epeius Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine
News

Epeius Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine

Epeius Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine
News

Epeius Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epeius Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Epeius Biotechnologies Corporation has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body.

With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic (or disease-seeking) targeting. These latest EU patents follow on the heels of a major clinical patent that was recently awarded in the USA for targeted gene delivery in vivo.

Together these clinical patents provide additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company’s leading anti-cancer agent Rexin-G®—the first and so far only tumor-targeted gene delivery system that has been successfully validated in the clinic.

Based on recent breakthroughs in tumor-targeting and nanotechnology, a new generation of biological anti-cancer agents that are highly selective for diseased tissues is currently in clinical development.

Anti-cancer agents such as Rexin-G® can be delivered by simple intravenous infusion, yet are programmed to seek-out and accumulate selectively in primary and metastatic lesions that have spread throughout the body, delivering a tumor-killing gene while sparing normal cells and tissues.
Advertisement